MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Owlstone Medical received up to $49.1 million from ARPA-H to develop the POSEIDON program, creating first-in-class synthetic-sensor based multi-cancer early detection tests for Stage I detection of 30+ solid tumors.

Researchers at McMaster University and MIT have discovered enterololin, a narrow-spectrum antibiotic that specifically targets disease-causing bacteria in inflammatory bowel diseases while preserving beneficial gut microbiome.

Cyclerion Therapeutics has secured intellectual property from MIT to relaunch as a neuropsychiatric company focused on treatment-resistant depression affecting 3 million Americans.

Researchers at the University of Illinois Hospital & Clinics validated the Sybil AI model's accuracy in predicting lung cancer risk within a predominantly Black patient population, addressing critical racial disparities in screening.

Researchers from NTU and MIT developed COMET, an AI model that predicts optimal lipid nanoparticle formulations for RNA medicine delivery, published in Nature Nanotechnology.

MIT researchers used generative AI to design two novel antibiotics capable of killing drug-resistant gonorrhea and MRSA in laboratory and animal tests.

Daré Bioscience received a $6 million non-dilutive grant installment, bringing total funding to $37.8 million of up to $49 million committed for DARE-LARC1 contraceptive development.

MIT engineers have developed an implantable device that automatically administers glucagon to prevent life-threatening hypoglycemic episodes in diabetics, with testing in mice showing blood sugar stabilization within 10 minutes.

Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics.

Korean biotech company ToolGen has filed patent infringement lawsuits against Vertex Pharmaceuticals in the UK and Netherlands over the world's first approved CRISPR gene therapy, Casgevy.